Insider Purchases: Inside the Buy
Tag: insider buying
Figma (FIG): Directors Buy In — Should You Collaborate?
🎨 Figma stock exploded out of the IPO gate, hitting highs nearly 5x insider purchase prices. With no profits, big Bitcoin bets, and stiff competition, is this design darling still worth the hype? Let’s sketch it out—icons, jokes, and all.
Arrow Electronics: A Straight Arrow, But the CEO Sees a Bullet
Arrow Electronics CEO Sean Kerins just bought nearly $1M of ARW stock. Is this undervalued tech distributor about to rebound, or just cruising under the radar? We take a shot at the bullseye—with puns and charts.
UPS: Shipping Value in an Expensive Market — Or Delivering a Value Trap?
UPS insiders are shipping signals of confidence 📬 with big stock purchases—even as growth slows and margins come under pressure. Should you get in on this box of value or beware what’s inside?
Progress Software CEO Buys In — Maybe It’s More Than Just... Progress?
Progress Software's CEO and a director are buying shares, signaling confidence as the company posts strong earnings and raises guidance. With institutional investors owning over 121% of the float, is this under-the-radar compounder set for a rerating?
Cogent Biosciences (COGT): The Biotech with a Plan, a Billion Cells, and a Bezuclastinib
Insiders are buying, trials are working, and Cogent just raised $230M. Meet bezuclastinib—the biotech drug with a Marvel name and real potential. 🧬💥
Will Profits From Marriott Vacations (VAC) Help You Unwind?
Insiders are buying, institutions are lounging, and dividends are flowing. Marriott Vacations Worldwide (VAC) might be your next profitable getaway — with a 3.9% yield and room to grow. But are there risks under the palm trees?
Insiders Are Buying ConocoPhillips. Should You?
Insiders are drilling into COP shares—and they're not alone. With a $10B return plan, strong reserves, and a smart buyout of Marathon Oil, ConocoPhillips might just be the contrarian pick of the year. Here's the fun, smart breakdown.
Moderna: Messenger RNA Medicines Powerhouse Sends A New Message — “Discount!”
Insiders dropped $6M on Moderna stock. With a massive mRNA pipeline and deep-pocketed backers, is this biotech beast ready to roar again?
Oscar Health: Its Own Is Shining and Insiders Knew!
Co-founder Joshua Kushner and Thrive Partners bought over $23 million of Oscar Health stock in late 2024. Since then? Record earnings, soaring revenue, and a stock still (surprisingly) within range. A healthy bet — or just a well-insured hunch?
CEO Bought Shares: Is Full House Worth Betting the House?
Full House Resorts is growing fast—but still bleeding cash. The CEO’s massive insider buy may hint at a turnaround, but with debt looming and expansion plans on the table, is FLL worth a gamble? We break it down—odds, icons, and all.